How should atrial fibrillation that occurs during a 5‑fluorouracil (5‑FU) infusion be managed?

Management of Atrial Fibrillation During 5-Fluorouracil Infusion

Stop the 5-FU infusion immediately when atrial fibrillation occurs, as cardiotoxicity is typically completely reversible upon cessation of the drug 1, 2.

Immediate Actions

1. Discontinue 5-FU Immediately

• Symptoms typically reverse within 5-60 minutes (mean 19 minutes) after stopping the infusion 2
• Do not wait for cardiac enzyme results or further testing before stopping the drug
• The temporal relationship between drug administration and arrhythmia onset is diagnostic 1

2. Acute Hemodynamic Assessment

If the patient is hemodynamically unstable (symptomatic hypotension, angina, cardiac failure, or shock):

• Perform immediate electrical cardioversion without waiting for anticoagulation 3
• Administer heparin bolus followed by continuous infusion (aPTT 1.5-2x control) 3
• Continue oral anticoagulation (INR 2-3) for at least 3-4 weeks post-cardioversion 3

If the patient is hemodynamically stable:

• Initiate rate control with beta-blockers (preferred), diltiazem, or verapamil 4
• Avoid digoxin as sole agent for acute rate control in this setting 4
• Obtain ECG, cardiac troponins, and continuous cardiac monitoring 1

3. Anticoagulation Decision

• Start anticoagulation based on CHA2DS2-VA score (age ≥75, hypertension, heart failure, diabetes, prior stroke/TIA) 4
• Consider low molecular weight heparin rather than warfarin or DOACs in cancer patients requiring multiple procedures or with unpredictable drug metabolism from chemotherapy 1
• If AF duration >24 hours or unknown, provide at least 3 weeks of anticoagulation before any elective cardioversion 5

Subsequent Chemotherapy Decisions

Do NOT Rechallenge with 5-FU

• An alternate antineoplastic regimen should be considered as first-line approach 1
• Cardiotoxicity recurs frequently with rechallenge 2

If No Alternative Exists (Rare Scenario)

Rechallenge may be attempted with extreme caution 1:

• Use bolus 5-FU instead of continuous infusion (lower cardiotoxicity risk)
• Reduce dose by 10-20% 6
• Administer in controlled setting with continuous cardiac monitoring
• Consider prophylactic transdermal nitroglycerin (though not universally effective) 6
• Inform patient of symptoms to report immediately

Common Pitfalls to Avoid

1. Do not continue 5-FU while investigating symptoms - immediate cessation is critical 1, 2
2. Do not use digoxin alone for rate control in acute paroxysmal AF 4
3. Do not withhold anticoagulation based on cancer diagnosis - use LMWH if oral agents are problematic 1
4. Do not assume prophylactic nitrates/calcium channel blockers will prevent recurrence - they are inconsistently effective 1, 6
5. Do not delay cardioversion for anticoagulation if patient is hemodynamically unstable 3

Key Clinical Context

5-FU cardiotoxicity occurs in approximately 8-18% of patients, typically 18-30 hours into infusion 7, 2. The mechanism involves coronary vasospasm rather than structural damage, explaining the rapid reversibility 1. Atrial fibrillation is one manifestation alongside chest pain, ST-T changes, and rarely ventricular arrhythmias 7, 8. Pre-existing cardiovascular disease does not predict who develops toxicity 7.